Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID PREVENT
NCT07602257Phase 4Not yet recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of ticagrelor, clopidogrel in acute coronary syndrome (ACS), sponsored by University of Ottawa Heart Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ticagrelorclopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07602257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602257.